Pic by Immo Wegmann via UnsplashJeito Capital has closed its second dedicated biopharma fund, Jeito II, on a record US$1.2 billion (€1 billion), making it the largest fund ever raised by a fully independent European biopharma-focused private equity firm. The move firmly places Jeito among the leading global backers of clinical stage innovation.
Tag Archive for: Alentis
Alentis TherapeuticsSwiss Alentis Therapeutics has raised US$181.4m in an oversubscribed Series D financing set to boost clinical development of its anti-Claudin-1 ADCs in solid tumours.